{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:26:15Z","timestamp":1775741175270,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T00:00:00Z","timestamp":1366588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis characterized by entry of activated T cells and antigen presenting cells into the central nervous system and subsequent autoimmune destruction of nerve myelin. Previous studies revealed that non-selective inhibition of poly(ADP-ribose) polymerases (PARPs) 1 and 2 protect against neuroinflammation and motor dysfunction associated with EAE, but the role of the PARP-2 isoform has not yet been investigated selectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>EAE was induced in mice lacking PARP-2, and neurological EAE signs, blood-spine barrier (BSB) permeability, demyelination and inflammatory infiltration were monitored for 35 days after immunization. Mice lacking PARP-2 exhibited significantly reduced overall disease burden and peak neurological dysfunction. PARP-2 deletion also significantly delayed EAE onset and reduced BSB permeability, demyelination and central nervous system (CNS) markers of proinflammatory Th1 and Th17 T helper lymphocytes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study represents the first description of a significant role for PARP-2 in neuroinflammation and neurological dysfunction in EAE.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1742-2094-10-49","type":"journal-article","created":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T18:39:19Z","timestamp":1366655959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis"],"prefix":"10.1186","volume":"10","author":[{"given":"Amit","family":"Kamboj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B","family":"Cossoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian L","family":"Stobart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A","family":"Dolhun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiina M","family":"Kauppinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"de Murcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,22]]},"reference":[{"key":"821_CR1_821","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ana.410310317","volume":"31","author":"DW Anderson","year":"1992","unstructured":"Anderson DW, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez M, Silberberg DH: Revised estimate of the prevalence of multiple sclerosis in the United States. \n                           Ann Neurol 1992, 31:333\u2013336.","journal-title":"Ann Neurol"},{"key":"821_CR2_821","first-page":"101","volume":"5","author":"N Girouard","year":"2011","unstructured":"Girouard N, Soucy N: Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. \n                           Patient Prefer Adherence 2011, 5:101\u2013108.","journal-title":"Patient Prefer Adherence"},{"key":"821_CR3_821","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0165-6147(03)00028-2","volume":"24","author":"O Neuhaus","year":"2003","unstructured":"Neuhaus O, Archelos JJ, Hartung HP: Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. \n                           Trends Pharmacol Sci 2003, 24:131\u2013138.","journal-title":"Trends Pharmacol Sci"},{"key":"821_CR4_821","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00019052-200106000-00003","volume":"14","author":"C Bjartmar","year":"2001","unstructured":"Bjartmar C, Trapp BD: Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. \n                           Curr Opin Neurol 2001, 14:271\u2013278.","journal-title":"Curr Opin Neurol"},{"key":"821_CR5_821","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1034\/j.1600-065x.2001.1840111.x","volume":"184","author":"H Link","year":"2001","unstructured":"Link H, Xiao BG: Rat models as tool to develop new immunotherapies. \n                           Immunol Rev 2001, 184:117\u2013128.","journal-title":"Immunol Rev"},{"key":"821_CR6_821","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/bies.20085","volume":"26","author":"JC Ame","year":"2004","unstructured":"Ame JC, Spenlehauer C, de Murcia G: The PARP superfamily. \n                           BioEssays 2004, 26:882\u2013893.","journal-title":"BioEssays"},{"key":"821_CR7_821","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.dnarep.2004.06.002","volume":"3","author":"A Huber","year":"2004","unstructured":"Huber A, Bai P, de Murcia JM, de Murcia G: PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. \n                           DNA Repair (Amst) 2004, 3:1103\u20131108.","journal-title":"DNA Repair (Amst)"},{"key":"821_CR8_821","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1093\/emboj\/cdg206","volume":"22","author":"J M\u00e9nissier de Murcia","year":"2003","unstructured":"M\u00e9nissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, Schreiber V, Am\u00e9 JC, Dierich A, LeMeur M, Sabatier L, Chambon P, de Murcia G: Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. \n                           EMBO J 2003, 22:2255\u20132263.","journal-title":"EMBO J"},{"key":"821_CR9_821","doi-asserted-by":"publisher","first-page":"23028","DOI":"10.1074\/jbc.M202390200","volume":"277","author":"V Schreiber","year":"2002","unstructured":"Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J, de Murcia G: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. \n                           J Biol Chem 2002, 277:23028\u201323036.","journal-title":"J Biol Chem"},{"key":"821_CR10_821","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.bjp.0704934","volume":"137","author":"A Chiarugi","year":"2002","unstructured":"Chiarugi A: Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. \n                           Br J Pharmacol 2002, 137:761\u2013770.","journal-title":"Br J Pharmacol"},{"key":"821_CR11_821","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/jpet.103.063214","volume":"310","author":"GS Scott","year":"2004","unstructured":"Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley JG, Szabo C, Hooper DC: The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. \n                           J Pharmacol Exp Ther 2004, 310:1053\u20131061.","journal-title":"J Pharmacol Exp Ther"},{"key":"821_CR12_821","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1177\/1352458511399113","volume":"17","author":"L Cavone","year":"2011","unstructured":"Cavone L, Aldinucci A, Ballerini C, Biagioli T, Moroni F, Chiarugi A: PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. \n                           Mult Scler 2011, 17:794\u2013807.","journal-title":"Mult Scler"},{"key":"821_CR13_821","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/ni.1775","volume":"10","author":"MF Farez","year":"2009","unstructured":"Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, Weiner HL: Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. \n                           Nat Immunol 2009, 10:958\u2013964.","journal-title":"Nat Immunol"},{"key":"821_CR14_821","doi-asserted-by":"publisher","first-page":"26070","DOI":"10.1074\/jbc.M109.013474","volume":"284","author":"V Selvaraj","year":"2009","unstructured":"Selvaraj V, Soundarapandian MM, Chechneva O, Williams AJ, Sidorov MK, Soulika AM, Pleasure DE, Deng W: PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. \n                           J Biol Chem 2009, 284:26070\u201326084.","journal-title":"J Biol Chem"},{"key":"821_CR15_821","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/brain\/awf133","volume":"125","author":"V Brundula","year":"2002","unstructured":"Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. \n                           Brain 2002, 125:1297\u20131308.","journal-title":"Brain"},{"key":"821_CR16_821","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jneuroim.2004.09.006","volume":"158","author":"F Giuliani","year":"2005","unstructured":"Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW: Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. \n                           J Neuroimmunol 2005, 158:213\u2013221.","journal-title":"J Neuroimmunol"},{"key":"821_CR17_821","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jns.2008.04.030","volume":"271","author":"T Touil","year":"2008","unstructured":"Touil T, Ciric B, Ventura E, Shindler KS, Gran B, Rostami A: Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis. \n                           J Neurol Sci 2008, 271:191\u2013202.","journal-title":"J Neurol Sci"},{"key":"821_CR18_821","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI200316721","volume":"111","author":"V Sanna","year":"2003","unstructured":"Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, Matarese G: Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. \n                           J Clin Invest 2003, 111:241\u2013250.","journal-title":"J Clin Invest"},{"key":"821_CR19_821","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","volume":"100","author":"SJ Szabo","year":"2000","unstructured":"Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. \n                           Cell 2000, 100:655\u2013669.","journal-title":"Cell"},{"key":"821_CR20_821","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17\n                           \n                    +\n                   \n                           T helper cells. \n                           Cell 2006, 126:1121\u20131133.","journal-title":"Cell"},{"key":"821_CR21_821","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1124\/jpet.104.066944","volume":"310","author":"A Iwashita","year":"2004","unstructured":"Iwashita A, Tojo N, Matsuura S, Yamazaki S, Kamijo K, Ishida J, Yamamoto H, Hattori K, Matsuoka N, Mutoh S: A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazo linone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia. \n                           J Pharmacol Exp Ther 2004, 310:425\u2013436.","journal-title":"J Pharmacol Exp Ther"},{"key":"821_CR22_821","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.mrfmmm.2010.01.016","volume":"686","author":"E Jelezcova","year":"2010","unstructured":"Jelezcova E, Trivedi RN, Wang XH, Tang JB, Brown AR, Goellner EM, Schamus S, Fornsaglio JL, Sobol RW: Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage. \n                           Mutat Res 2010, 686:57\u201367.","journal-title":"Mutat Res"},{"key":"821_CR23_821","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1039\/C0OB00665C","volume":"9","author":"PT Sunderland","year":"2011","unstructured":"Sunderland PT, Dhami A, Mahon MF, Jones LA, Tully SR, Lloyd MD, Thompson AS, Javaid H, Martin NM, Threadgill MD: Synthesis of 4-alkyl-, 4-aryl- and 4-arylamino-5-aminoisoquinolin-1-ones and identification of a new PARP-2 selective inhibitor. \n                           Org Biomol Chem 2011, 9:881\u2013891.","journal-title":"Org Biomol Chem"},{"key":"821_CR24_821","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.4049\/jimmunol.0901568","volume":"184","author":"F Nasta","year":"2010","unstructured":"Nasta F, Laudisi F, Sambucci M, Rosado MM, Pioli C: Increased Foxp3\n                           \n                    +\n                   \n                           regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. \n                           J Immunol 2010, 184:3470\u20133477.","journal-title":"J Immunol"},{"key":"821_CR25_821","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1038\/sj.emboj.7601301","volume":"25","author":"J Y\u00e9lamos","year":"2006","unstructured":"Y\u00e9lamos J, Monreal Y, Saenz L, Aguado E, Schreiber V, Mota R, Fuente T, Minguela A, Parrilla P, de Murcia G, Almarza E, Aparicio P, M\u00e9nissier-de Murcia J: PARP-2 deficiency affects the survival of CD4\n                           \n                    +\n                  \n                           CD8\n                           \n                    +\n                   \n                           double-positive thymocytes. \n                           EMBO J 2006, 25:4350\u20134360.","journal-title":"EMBO J"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-10-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1742-2094-10-49\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-2094-10-49.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:06:59Z","timestamp":1630537619000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/1742-2094-10-49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1186\/1742-2094-10-49","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,22]]},"assertion":[{"value":"16 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"821"}}